4-fluoro-3-methoxy-benzamide | 874804-32-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-3-methoxy-benzamide
• 英文别名: 4-Fluoro-3-methoxybenzamide
• CAS: 874804-32-7
• 化学式: C₈H₈FNO₂
• 分子量: 169.155
• InChiKey: WBXUKOBYJXNSNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluoro-3-methoxy-benzamide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 8.0h， 生成 N-(2,2-dimethoxyethyl)-5-[5-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-1-yl]pyridin-2-amine
  参考文献：
  名称：

  IMIDAZO[1,2-A]PYRIDINE DERIVATIVES

  摘要：

  The current invention relates to compounds of the formula (I), wherein the substituents are as defined in claim 1, to processes and methods for preparing compounds of formula (I), to agrochemical compositions comprising compounds of formula (I) as defined in claim 1, to preparation of these compositions and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.

  公开号：

  WO2024126404A1
• 作为产物：
  描述：

  4-氟-3-甲氧基苯乙酸 在 copper(I) oxide 、 ammonium hydroxide 、 氧气 作用下， 以 水 为溶剂， 反应 32.0h， 以32%的产率得到4-fluoro-3-methoxy-benzamide
  参考文献：
  名称：

  Synthesis of Primary Amides via Copper-Catalyzed Aerobic Decarboxylative Ammoxidation of Phenylacetic Acids and α-Hydroxyphenylacetic Acids with Ammonia in Water

  摘要：

  A Cu2O-catalyzed aerobic oxidative decarboxylative ammoxidation to primary benzamides from phenylacetic acids and alpha-hydroxyphenylacetic acids is developed. A variety of primary benzamides could be prepared smoothly, in good to excellent yields, by means of a one-pot domino protocol combining decarboxylation, dioxygen activation, oxidative C-H bond functionalization, and amidation reactions.

  DOI：

  10.1021/ol403586c

文献信息

• DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS
  申请人：Brotherton-Pleiss Christine E.

  公开号：US20100160388A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  公式I的化合物：或其药用可接受的盐，其中m、n、R1、R2、R3、R4和R5按本文件定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与P2X7嘌呤能受体相关疾病的方法。
• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
• Cyclic amine compound
  申请人：Yamamoto Satoshi

  公开号：US20100152236A1

  公开（公告）日：2010-06-17

  A compound represented by the formula (I) wherein ring A is a 5- to 8-membered ring optionally having further substituent(s) other than R 6 , R 7 and R 8 , R 1 is an electron-withdrawing group, R 2 , R 3 , R 4 and R 5 are each independently a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R 6 is a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R 7 is a cyano group, a nitro group, an acyl group optionally having substituent(s), an optionally esterified or amidated carboxyl group or a hydrocarbon group optionally having substituent(s), or R 6 and R 7 optionally form, together with the carbon atom bonded thereto, a ring optionally having substituent(s), and R 8 is a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, or a salt thereof has a superior action as an androgen receptor modulator, and is useful for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia, osteoporosis and the like.

  化合物的化学式为（I），其中环A是一个5到8个成员的环，可以选择性地具有除R6、R7和R8以外的其他取代基，R1是一个电子吸引基团，R2、R3、R4和R5分别是氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，R6是卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，R7是氰基、硝基、可选择具有取代基的酰基、可选择酯化或酰胺化的羧基或可选择具有取代基的碳氢基团，或R6和R7可选择地与其键合的碳原子一起形成一个可选择具有取代基的环，R8是氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，或其盐具有卓越的雄激素受体调节剂作用，并且用于预防或治疗性腺机能减退、男性更年期障碍、虚弱、消瘦、骨质疏松等。
• CYCLIC AMINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911743A1

  公开（公告）日：2008-04-16

  A compound represented by the formula (I) wherein ring A is a 5- to 8-membered ring optionally having further substituent(s) other than R6, R7 and R8, R1 is an electron-withdrawing group, R2, R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R6 is a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R7 is a cyano group, a nitro group, an acyl group optionally having substituent(s), an optionally esterified or amidated carboxyl group or a hydrocarbon group optionally having substituent(s), or R6 and R7 optionally form, together with the carbon atom bonded thereto, a ring optionally having substituent(s), and R8 is a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, or a salt thereof has a superior action as an androgen receptor modulator, and is useful for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia, osteoporosis and the like.

  由式 (I) 代表的化合物 其中环 A 是一个 5 至 8 元环，除 R6、R7 和 R8 外，还可选择具有其他取代基、 R1 是一个抽电子基团、 R2、R3、R4 和 R5 各自独立地为氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团、 R6 是卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团、 R7 是氰基、硝基、可选择具有取代基的酰基、可选择酯化或酰胺化的羧基或可选择具有取代基的烃基，或 R6 和 R7 可选择与其键合的碳原子一起形成可选择具有取代基的环，以及 R8 是氢原子、卤素原子、通过碳原子键合的基团、通过氮原子键合的基团、通过氧原子键合的基团或通过硫原子键合的基团，或其盐具有作为雄激素受体调节剂的优异作用，可用于预防或治疗性腺功能减退、男性性腺功能紊乱、虚弱、恶病质、骨质疏松症等。
• NOVEL ADAMANTANE DERIVATIVE COMPOUND
  申请人：Amorepacific Corporation

  公开号：EP3187486A1

  公开（公告）日：2017-07-05

  Disclosed is a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. Also disclosed is a method for preparing a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. The novel adamantane derivative compound or the like has an excellent anti-androgenic effect.

  公开了一种新型金刚烷衍生物化合物、其异构体、其药学上可接受的盐、其原药、其水合物或其溶液。还公开了一种制备新型金刚烷衍生物化合物、其异构体、其药学上可接受的盐、其原药、其水合物或其溶液的方法。新型金刚烷衍生物化合物或类似物具有优异的抗雄激素作用。